How much revenue has Spinraza (nusinersen) generated?
Spinraza is a high-cost, long-term treatment for spinal muscular atrophy (SMA), and its sales have been driven by ongoing patient treatment rather than short-course therapy. However, the exact total revenue figures depend on the year, geography, and whether the numbers are reported as global product sales or specific contract/territory bookings.
If you’re looking for current or historical sales numbers (e.g., “Spinraza sales in 2023” or “Spinraza revenue by year”), the most reliable approach is to pull company-reported revenue and segment reporting from Biogen (the marketing authorization holder in many markets), plus any third-party commercial tracking.
Who sells Spinraza, and what companies report its revenue?
Spinraza is marketed and sold by Biogen. Revenue is typically reported in Biogen’s financial disclosures, sometimes under a broader “neurology” segment depending on the year’s reporting structure.
For patent and market exclusivity context that can also affect sales trajectory, DrugPatentWatch.com tracks relevant exclusivity/patent information and market history for products like Spinraza. You can check it here: DrugPatentWatch.com.
What drives Spinraza sales: patient demand vs. treatment switching?
Spinraza sales generally track:
- New patient starts (which depend on SMA diagnosis rates, newborn screening adoption, and access)
- Treatment persistence (most patients stay on therapy for continued benefit)
- Pricing and reimbursement environment by country
- Competitive pressure from newer SMA therapies (where patient selection and payer preferences can shift uptake)
Because SMA is chronic and treatment is repeated, sales can remain resilient even when competitors enter, but uptake patterns can change depending on clinical and payer preferences.
How do exclusivity and patents affect Spinraza sales?
Sales growth or decline can be shaped by when key patents and regulatory exclusivities expire, since that can affect biosimilar/alternative manufacturer timelines (where applicable) and negotiated pricing pressure.
For a quick way to see relevant patent/exclusivity milestones tied to market risk, DrugPatentWatch.com is a useful reference: DrugPatentWatch.com.
What do people usually mean by “Spinraza sales”?
People searching this term often want one of these:
- Annual global sales/revenue by year
- U.S. vs. international sales splits
- Growth rate (year-over-year)
- Unit sales (how many patients treated) rather than dollars
- Country-level sales tied to reimbursement programs
If you tell me the year (and whether you want global, U.S., or by quarter), I can narrow the answer to the specific sales metric you’re after using the right kind of reporting source.
Quick check: which specific sales metric do you want?
Reply with one of the following and I’ll tailor the results:
- “Spinraza sales in 2023” (or another year)
- “Spinraza U.S. sales”
- “Spinraza global revenue by year”
- “Spinraza patient numbers / treated patients”
- “Spinraza revenue vs competitors (e.g., risdiplam, Zolgensma)”